4.7 Review

Potential and Applications of Nanocarriers for Efficient Delivery of Biopharmaceuticals

期刊

PHARMACEUTICS
卷 12, 期 12, 页码 -

出版社

MDPI
DOI: 10.3390/pharmaceutics12121184

关键词

biopharmaceuticals; recombinant DNA technology; delivery and formulation challenges; nanocarriers; proteins; monoclonal antibodies; enzymes; vaccines; cytokines; hormones

资金

  1. Basic Science Research Program of the National Research Foundation of Korea (NRF) - Ministry of Science and ICT [NRF-2020R1F1A1072657]
  2. Korea Ministry of Environment (MOE) [2019002490005 1485016231, 2019002490004 1485016253]
  3. National Research Foundation of Korea [4120200813639] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

向作者/读者索取更多资源

During the past two decades, the clinical use of biopharmaceutical products has markedly increased because of their obvious advantages over conventional small-molecule drug products. These advantages include better specificity, potency, targeting abilities, and reduced side effects. Despite the substantial clinical and commercial success, the macromolecular structure and intrinsic instability of biopharmaceuticals make their formulation and administration challenging and render parenteral delivery as the only viable option in most cases. The use of nanocarriers for efficient delivery of biopharmaceuticals is essential due to their practical benefits such as protecting from degradation in a hostile physiological environment, enhancing plasma half-life and retention time, facilitating absorption through the epithelium, providing site-specific delivery, and improving access to intracellular targets. In the current review, we highlight the clinical and commercial success of biopharmaceuticals and the overall applications and potential of nanocarriers in biopharmaceuticals delivery. Effective applications of nanocarriers for biopharmaceuticals delivery via invasive and noninvasive routes (oral, pulmonary, nasal, and skin) are presented here. The presented data undoubtedly demonstrate the great potential of combining nanocarriers with biopharmaceuticals to improve healthcare products in the future clinical landscape. In conclusion, nanocarriers are promising delivery tool for the hormones, cytokines, nucleic acids, vaccines, antibodies, enzymes, and gene- and cell-based therapeutics for the treatment of multiple pathological conditions.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据